Olympus Launches ViziShot 2 25 G Needle

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

ViziShot 2 25 G needle for Endobronchial Ultrasound Transbronchial Aspiration (EBUS-TBNA) was launched today. The news was reported by Olympus.

This device is a part of the Olympus EBUS Solution which offers a comprehensive solution for diagnosing and staging lung cancer. The Olympus EBUS system is the only solution recommended for both lymph node sampling and peripheral lesion detection.

“As the only company manufacturing and selling both bronchoscopes and needles, Olympus is proud to expand our EBUS-TBNA product family portfolio with the 25 G EBUS-TBNA needle. Our comprehensive pulmonary solutions bring great value to our physician customers striving to advance diagnosis and staging capabilities for lung disease and lung cancer,” said Lynn Ray, Vice President, General Manager, Global Respiratory, Olympus.

EBUS-TBNA, a procedure used in the diagnosis and staging of lung cancer, allows physicians to visualize diseased tissue, lymph nodes or lesions beyond the walls of the airways. Samples from parts of the lymph node that require further investigation can be taken using a specialized aspiration needle.

The ViziShot 2 25 G, is the smallest gauge size of the Olympus EBUS-TBNA needle portfolio. Benefits of the smaller lumen and enhanced design features of the 25 G needle include:

  • High Quality Samples: Even with a smaller lumen, the needle is able to obtain sufficient quantities of high-quality specimen needed for establishing a diagnosis and reliable staging.
  • Increased Accessibility during EBUS-TBNA: The small diameter of the 25 G EBUS-TBNA needle enhances scope angulation leading to increased accessibility, and flexibility and of difficult-to-reach lymph nodes.
  • Improved Puncture Capabilities: This needle requires less puncture force to the sample due to the curved edge back-cut needle tip design feature.
  • Clear Target Visualization: Clear ultrasound echogenicity is maintained due to the dimpled needle design.

“A 25-gauge needle is something I have always wanted available in our lab,” said Ramyar Madhavi, MD of Keck School of Medicine of the University of Southern California. “From our point of view, the needle tip is sharper; it handles easily and provides a more than adequately sized, high-quality specimen. Having this needle allows me to feel more comfortable when proceeding with EBUS on patients for whom discontinuing anticoagulant therapy is not an option.”

Among both men and women, lung cancer is the leading cause of cancer-related deaths in the U.S., according to the Centers for Disease Control and the American Cancer Society. It is estimated that over 370 Americans will die each day from the disease in 2020.1 Since the announcement of new lung cancer screening recommendations for high-risk patients by the U.S. Preventive Services Task Force in July 2013, we have seen a 5 percent decline in lung-cancer related deaths2, lending evidence to the effectiveness of early diagnosis and accurate staging of lung cancer.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.